title: Clinical efficacy of subgingivally delivered 1.2-mg simvastatin in the treatment of individuals with Class II furcation defects: a randomized controlled clinical trial.
abstract: BACKGROUND
  Simvastatin (SMV) assists in bone regeneration and has an anti-inflammatory effect when delivered or applied locally. The present clinical trial is designed to investigate the effectiveness of 1.2-mg SMV as a local drug delivery system as an adjunct to scaling and root planing (SRP) for the treatment of Class II furcation defects.
  
  
  METHODS
  Seventy-two patients with mandibular buccal Class II furcation defects were randomized and categorized into two treatment groups: SRP plus placebo (group 1) and SRP plus 1.2-mg SMV (group 2). Clinical parameters were recorded at baseline before SRP and at 3 and 6 months; they included modified sulcus bleeding index (mSBI), probing depth (PD), and relative vertical (RVAL) and horizontal (RHAL) attachment levels. At baseline and after 6 months, radiologic assessment of bone defect fill was performed.
  
  
  RESULTS
  Both therapies resulted in significant improvements. The decrease in mSBI score at 6 months was greater in group 2 (2.02 ± 0.23) compared with group 1 (1.80 ± 0.22). The mean decrease in PD at 6 months was 1.30 ± 1.0 and 4.05 ± 1.31 mm in groups 1 and 2, respectively. A significantly greater gain in mean RVAL and RHAL was found in group 2 than in group 1 (P <0.05). Furthermore, significantly greater mean percentage of bone fill was found in group 2 (25.16%) compared with group 1 (1.54%).
  
  
  CONCLUSIONS
  Locally delivered SMV provides a comfortable and flexible method to improve clinical parameters and also to enhance bone formation.
authors.affiliation: Department of Periodontics, Government Dental College and Research Institute, Bangalore, Karnataka, India. periodonticsgdcri@gmail.com
authors.forename: A R
authors.initials: AR
authors.lastname: Pradeep
authors.forename: N
authors.initials: N
authors.lastname: Priyanka
authors.forename: Nitish
authors.initials: N
authors.lastname: Kalra
authors.forename: Savitha B
authors.initials: SB
authors.lastname: Naik
authors.forename: Sonender P
authors.initials: SP
authors.lastname: Singh
authors.forename: Santosh
authors.initials: S
authors.lastname: Martande
mesh_terms: D000328:Adult; D016301:Alveolar Bone Loss / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001861:Bone Regeneration / Q000187:drug effects*; D016009:Chi-Square Distribution; D012534:Dental Scaling; D004337:Drug Carriers; D005260:Female; D005782:Gels; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008747:Methylcellulose; D008875:Middle Aged; D010512:Periodontal Index; D011859:Radiography; D019821:Simvastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D016037:Single-Blind Method; D018709:Statistics, Nonparametric; D015607:Stents
chemical_list: D004337:Drug Carriers; D005782:Gels; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008747:Methylcellulose; D019821:Simvastatin